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Abstract 
Objectives: Arterial and systolic elastance are important parameters determining effective 
functional interaction of heart and vessels. The aims of this study were to (i) compare arterial 
[arterial elastance index (EaI)] and ventricular [End-systolic elastance (Ees) and End-diastolic 
elastance (Eed)] elastance in subjects with obstructive sleep apnoea (OSA) and patients with 
treated ‘high-risk’ hypertension (HHT), and (ii) test whether these parameters in OSA 
patients can be improved by continuous positive airway pressure (CPAP) therapy. 
Methods: Echocardiographic parameters of cardiac and vascular stiffness (EaI, Ees and Eed) 
were quantified in 28 patients with OSA (mean [SD] age 51 [11] years, 79% male) and 28 
treated subjects with HHT (mean [SD] age 48 [12] years, 61% male). Twenty three OSA 
patients were treated with CPAP for median of 26 weeks. Ea was calculated from stroke 
volume and systolic BP and adjusted by body area (EaI). Both study groups had preserved 
and comparable left ventricle (LV) contractility.  
Results: There was no significant differences in arterial elastance index (EaI, p=0.94), end-
systolic elastance (Ees, p=0.5), end-diastolic elastance (Eed, p=0.63) and arterial-ventricular 
interaction (Ees/Ea, p=0.62) between OSA and HHT groups. After CPAP therapy, there was 
a significant reduction in arterial elastance index (EaI; paired t-test, p=0.013), and arterial-
ventricular interaction (Ees/Ea; paired t-test, p=0.004). End-systolic elastance (Ees, p=0.17), 
end-diastolic elastance (Eed, p=0.66) parameters did not change significantly.  
Conclusions: OSA patients and HHT patients have similar parameters of elastance and 
ventricular-arterial coupling. CPAP treatment in OSA patients significantly improved 
ventricular-arterial coupling. 
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Condensed abstract 
There was no significant differences in arterial elastance index (EaI, p=0.94), end-systolic 
elastance (Ees, p=0.5), end-diastolic elastance (Eed, p=0.63) and arterial-ventricular 
interaction (Ees/Ea, p=0.62) between obstructive sleep apnoea and high risk hypertension 
groups. After continuous positive airway pressure therapy, there was a significant reduction 
in arterial elastance index (EaI), and arterial-ventricular interaction (Ees/Ea). End-systolic 
elastance (Ees), end-diastolic elastance (Eed) parameters did not change significantly. As a 
result patients with obstructive sleep apnoea and high risk hypertension have similar 
parameters of elastance and ventricular-arterial coupling. Continuous positive airway 
pressure treatment in patients with obstructive sleep apnoea significantly improves 
ventricular-arterial coupling. 
 
Key words: obstructive sleep apnoea; arterial elastance; ventricular elastance; ventricular-
arterial couplings 
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Introduction 
 
Obstructive sleep apnoea (OSA) is a pathological condition associated with recurrent 
hypoxia, disturbed sleep, and ultimately excessive negative intrathoracic pressure that leads 
to detrimental effects on cardiovascular system and an increased cardiovascular morbidity.[1, 
2] Mechanisms of OSA-related cardiac and arterial damage are diverse and still insufficiently 
understood. Hypertension is common in OSA and predisposes to cardiac diastolic 
dysfunction, arterial stiffening as well as endothelial dysfunction.[3-6] The pathogenic 
mechanisms of OSA also involve increase sympathetic activity, inflammation and oxidative 
stress, and might thus disturb cardiovascular performance even in patients without overt 
hypertension.  
 
Impairment of cardiac and vascular elastic properties is recognised as a critical element of 
cardiovascular pathophysiology.[7, 8] Large arteries do not just server as passive conduits of 
blood, but are active component of a variety of cardiovascular functions.[9] Increased arterial 
and cardiac stiffness are also important contributors to cardiac systolic and diastolic 
dysfunction and is determined by the composition of the extracellular matrix, arterial smooth 
muscle tone and relaxation capacity of cardiomyocytes.[10] Ability of normal large arteries 
to stretch during systole and to maintain some of the blood volume (and to consequently 
return it to the circulation during diastole) is crucial for smoothening cyclic fluctuations in 
blood pressure (BP). This process also reduces cardiac afterload and improves coronary 
perfusion in diastole. 
 
Arterial and left ventricular (LV) actions (i.e., ventricular-arterial coupling) are normally well 
coordinated and can be measured using echocardiography, as parameters of arterial and 
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cardiac elastance.[11] Ventricular-arterial interactions can be disturbed in conditions 
associated with increased arterial and cardiac stiffness, such as hypertension. Given that there 
is well documented enhanced arterial stiffness in OSA, it is plausible that ventricular-arterial 
coupling can also be impaired in OSA, but this has not been previously investigated.[12] 
 
Continuous positive airway pressure (CPAP) treatment of mild to moderate OSA has been 
shown to improve symptoms, quality of life and outcomes, and has been accepted as the 
‘gold standard’ treatment in OSA[13].  The effects of CPAP on cardiovascular function in 
hypertension free OSA patients without pre-existing cardiovascular disease has not been 
established.[14, 15] The data on effect of CPAP on cardiac function are controversial, 
although scarce data are available on the effect of CPAP treatment on the parameters of 
arterial and cardiac elastance.[16-18]  
 
In this study, we tested the hypothesis that abnormal arterial [arterial elastance (Ea); arterial 
elastance index (EaI)] and ventricular [End-systolic elastance (Ees) and End-diastolic 
elastance (Eed)] elastances are present in untreated OSA patients, compared to treated ‘high-
risk’ hypertension (HHT) patients, and second, that these parameters in OSA can be 
improved after CPAP therapy. 
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Methods 
 
In this prospective study twenty eight consecutive subjects with a confirmed diagnosis of 
moderate-severe OSA have been compared with 28 treated ‘high risk hypertensives’ (HHT). 
OSA group included subjects with aponea-hypopnoea index (AHI)>15, established by multi-
channel polysomnography (FSI Grey Flash recorder, Stowood Scientific Instruments Ltd, 
Oxford UK) and recruited from the Sleep laboratory in City Hospital, Birmingham, UK.  
HHT was defined by the presence of established hypertension associated with one or more of 
the following cardiovascular risk factors: LV hypertrophy (Sokolow-Lyon or Cornell voltage 
criteria), age >55 years, peripheral vascular disease, or known family history of CAD, a 
definition used in contemporary clinical trials[19]. Exclusion criteria were: secondary 
hypertension related to renal, renovascular or endocrine causes, CAD, valvular heart disease, 
LV ejection fraction <50%, diabetes mellitus, liver disease, serum creatinine >200 µmol/L, 
malignancy, recent (<3 months) arterial or venous thromboembolic disease, active infections 
and/or a history of inflammatory or connective tissue disorders. 
 
Participants were asked to abstain from alcohol, tea, coffee and smoking for 24 hours prior to 
the study. Participants were asked not to take their medications on the study day. All scans 
were done in a darkened, quiet, temperature controlled room after rest for 15-20 minutes. 
After baseline scan, patients with OSA were provided with an automated CPAP device 
(REMstar Pro M Series with C-Flex, Phillips Respironics, Pennsylvania, USA). CPAP 
compliance was monitored/recorded throughout the study at regular intervals. It was 
considered satisfactory when used minimum 4 hours per night for at least 6 nights per week. 
Twenty three OSA patients completed this part of the study with a mean duration of CPAP 
therapy of 26 weeks prior to the second examination. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7 
 
 
Echocardiography 
M-mode, 2D echocardiography (2DE), tissue Doppler imaging (TDI) and 3D 
echocardiography (3DE) were performed using Phillips iE33 ultrasound machine (Bothel, 
WA, USA) and analysed by off-line QLAB software (Xcelera, Phillips Ultrasound 
Quantification Module, USA). All parameters were measured in triplicate and averaged. 
Measurements of arterial-vascular interaction were made as reported and validated 
previously.[20-22] Effective arterial elastance index (EaI) was calculated as an effective 
arterial elastance (Ea, based on 3DE stroke volume and systolic BP) adjusted by body area. 
End-systolic elastance (Ees) was calculated using systolic and diastolic BP, stroke volume, 
pre-ejection and total systolic times. End-dystolic elastance (Eed) was established from the 
ratio of mitral inflow early diastolic filling velocity and the mitral annular early diastolic TDI 
velocity (E’) divided by volume filling during diastole. In the absence of significant aortic 
regurgitation, stroke volume can be used as an indicator of ventricular filling volume. The 
Ea/Ees ratio was used as a measure of arterial-ventricular interaction. The inter- and intra-
observer variability for echocardiography parameters was 11% and 6.8%, respectively. 
 
Power calculation 
On the basis on our previous work on parameters of elastance, we calculated that a sample 
size of at least 15 patients in each group would have an 80% power to detect a significant 
difference ≥0.5 standard deviation in effective arterial elastance.[22]  
 
Statistical methods 
Data are presented as mean [standard deviations, SD] for normally distributed data; or 
median [inter-quartile range, IQR] for non-normally distributed data. Comparisons between 
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OSA and HHT groups were performed by unpaired T-test (for normally distributed variables) 
or Mann-Whitney test (for non-normally distributed variables). Paired T-test (for normally 
distributed variables) or Mann-Whitney test (for non-normally distributed variables) was used 
to assess effect of CPAP therapy on OSA patients. Correlation analysis was performed using 
Pearson method for normally-distributed data and Spearman method for non-normally 
distributed variables. A two-tailed p-value of <0.05 was considered statistically significant. 
SPSS 17 (SPSS, Inc, Chicago, Illinois, USA) software was used to perform the analysis. 
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Results 
 
Groups of patients with OSA and HHT were well matched for age, sex, body mass index, 
cardiovascular risk factors and LV ejection fraction (Table 1). Patients in the OSA group 
were free of pharmaceutical therapy at the time of the study. In the hypertension group 15 
(54%) patients received an angiotensin enzyme inhibitors or angiotensin receptor antagonist, 
8 (29%) a calcium channel blocker, 9 (32%) a diuretic, 5 (18%) a α1-blocker, 3 (11%) a beta-
blocker, 1 (4%) hydralazine, 4 (14%) a statin and 1 (4%) aspirin. Twenty three OSA patients 
completed follow up of at least 23 weeks of CPAP therapy (mean follow-up of 26 weeks). 
 
Vascular-ventricular interactions 
There were no significant differences in arterial elastance index (EaI, p=0.94), end-systolic 
elastance (Ees, p=0.50), end-diastolic elastance (Eed, p=0.63) and arterial-ventricular 
interaction (Ea/Ees, p=0.62) between OSA and HHT groups (Table 1). In the OSA group, 
Eed was positively correlated with age (r=0.40, p=0.037) and Ees was positively correlated 
with heart rate  (r=0.42; p=0.026) 
 
Effect of CPAP therapy in obstructive sleep apnoea patients 
Systolic blood pressure was significantly reduced after CPAP therapy (p<0.001), and there 
was a significant improvement in LVEF on 2DE (p=0.02) (Table 2).  
 
CPAP therapy resulted in significant reduction in arterial elastance index (EaI, p=0.013), and 
arterial-ventricular interaction (Ees/Ea, p=0.004) (Figure 1). End-systolic elastance (Ees, 
p=0.17), end-diastolic elastance (Eed, p=0.66) parameters did not change significantly. 
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Discussion 
 
In this study, we show for the first time that arterial elastance and arterial-ventricular 
interactions in patients with OSA are significantly improved by CPAP therapy. We found that 
OSA patients and HHT patients had similar parameters of elastance and ventricular-arterial 
coupling.  The non-invasive nature of our approach makes it applicable for clinical use and 
particularly for monitoring of treatment effects, for example, with CPAP therapy.  Indeed, 
parameters of elastance used in the study provide an advance in the assessment of the 
cardiovascular elastic properties and the echocardiographic method has been validated by 
direct comparisons with invasive analysis of pressure-volume curves.[20, 21]  
 
Of interest, the study has not found any difference in parameters of elastance and vascular-
cardiac interactions between normotensive subjects with OSA and patients with HHT. This 
indicates presence of abnormal ventricular-arterial coupling in OSA irrespectively of 
hypertensive status that is common in this condition. 
 
Arterial elastance characterises the artery's capacity to expand and contract in synchrony with 
cardiac cycle. Cardiac elastance reflects increased myocardial mass, a shift in the myocardiac 
content characterised by reduced myocyte number and enhanced collagen deposition and 
cross-linking.[23] Impaired cardiac elastance is likely to contribute to cardiac overload and 
diastolic dysfunction common in OSA, whilst high Ees may result in increased myocardial 
oxygen consumption, and disturb myocardial perfusion reserve.[24] Appropriate coupling of 
heart to artery (e.g., estimated by the Ea/Ees ratio) is essential for effective transfer of blood 
from heart to the peripheral circulation without excessive changes in blood pressure and it is 
a significant factor of overall cardiovascular performance..[25, 26] Accordingly, our study 
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observations of equally abnormal ventricular-arterial interactions in OSA and HHT can 
represent another factor mediating the high risk of cardiovascular events in OSA. 
 
The exact mechanisms by which CPAP improves cardiac and vascular elastance are not 
entirely clear at present. These are likely to be mediated by a reduction in blood pressure and 
intrathoratic pressure, and vascular tone, and amelioration of hypoxia and related beneficial 
effects on LV remodelling.[27]  During episodes of obstructive apnoeas the patients 
experience negative intrathoracic pressure against an occluded upper airway, which leads to 
elevation of LV transmural pressure and LV afterload.[28] Cyclic increases in the BP at the 
end of apnea further contribute to raise in LV afterload.[28] These disturbances in cardiac 
haemodynamics could be diminished by regular CPAP usage. Also, improvement in sub-
endocardial perfusion and enhanced oxyhaemoglobin concentrations could play a role.[29] 
Our study results are also consistent with previous reports on improvement in vascular 
function in patients with OSA by treatment with CPAP and the effects might have also been 
mediated by improvements in endothelial function, as previously demonstrated.[30, 31] 
 
Limitations 
The study groups are relatively small and larger studies are essential to established outcome-
related impact on the observed changes in elastance after CPAP therapy. Also, the study does 
not provide a complete mechanistic explanation of the findings, which would also need to be 
done in appropriately designed studies. 
 
Conclusions 
OSA patients and HHT patients have similar parameters of elastance and ventricular-arterial 
coupling. CPAP treatment in OSA patients significantly improved arterial elastance and 
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ventricular-arterial coupling, which may contribute to the clinical effectiveness of this 
treatment. 
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Figure 1. Effect of continuous positive airway pressure (CPAP) therapy on parameters of 
elastance.  
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Table 1. Demographic and clinical characteristic of the study groups  
 OSA (n=28) HHT (n=28) p value 
Age, years 51 [11] 48 [12] 0.39 
Male, n [%] 22 [79] 17 [61] 0.15 
Systolic BP, mm Hg 138 [16] 148 [22.8] 0.06 
Diastolic BP, mm Hg 82 [12] 84 [10] 0.43 
Heart rate, bpm 72 [12] 68 [14] 0.26 
Body mass index, kg/m2  31 [4] 30 [6] 0.83 
Total cholesterol, mmol/l 5.0 [1.1] 5.2 [1.0] 0.40 
Smoking, n [%] 11 [39] 12 [43] 0.79 
Ejection fraction (2D), % 66 [10] 68 [9] 0.45 
Arterial elastance index (EaI), 
mm Hg/ml/m2 
1.3 [0.5] 1.3 [0.5] 0.94 
End-systolic elastance (Ees), 
mm Hg/ml 
3.5 [1.4] 3.2 [1.2] 0.50 
End-diastolic elastance (Eed), 
mm Hg/ml 
0.10 [0.06-0.14] 0.11 [0.08-0.13] 0.63 
Ea/Ees 0.81 [0.19] 0.83 [0.19] 0.62 
Values expressed as mean [SD] or median [IQR]. HHT, High risk hypertension; OSA, 
obstructive sleep apnoea 
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Table 2. Effect of continuous positive airway pressure therapy in obstructive 
sleep apnoea 
 Baseline After p value 
Systolic BP, mm Hg 140 [16] 130 [10] <0.001 
Diastolic BP, mm Hg 82 [13] 79 [7] 0.18 
Ejection fraction (2D), % 65 [10] 69 [7] 0.02 
Arterial elastance index (EaI), 
mm Hg/ml/m2 
1.3 [0.5] 1.07 [0.4] 0.013 
End-systolic elastance (Ees), 
mm Hg/ml 
3.4 [1.5] 3.1 [1.3] 0.17 
End-diastolic elastance (Eed), 
mm Hg/ml 
0.10 [0.06-0.15] 0.10 [0.07-0.14] 0.66 
Ea/Ees 0.82 [0.19] 0.73 [0.13] 0.004 
Values expressed as mean [SD] or median [IQR] 
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